BlossomHill Therapeutics
PrivateLast Round
Series B
Extension
Dec 10, 2025
Total Funding Raised
$343.65M
Momentum Score
25 /100
Company Overview
BlossomHill Therapeutics, Inc. is a biopharmaceutical company that discovers and develops small molecule medicines for the treatment of high-need cancers and autoimmune diseases. Founded in June 2020 by Dr. J. Jean Cui and Dr. Y. Peter Li, the co-founders of Turning Point Therapeutics, the company aims to create next-generation precision medicines. BlossomHill's approach involves designing novel chemical entities from the ground up to overcome treatment resistance mechanisms. The company is headquartered in San Diego, California, and is backed by prominent life science investors. In February 2024, BlossomHill closed a $100 million Series B financing to advance its lead oncology programs into clinical trials and continue building its pipeline.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BlossomHill Therapeutics Comps
Public and private peers based on sector, stage, and business model.
BlossomHill Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 10, 2025 | ||||
| Series B | Feb 29, 2024 | ||||
| Series B | Dec 28, 2023 | ||||
| Series A | Mar 3, 2021 |
Key People
Founding team and executive leadership
BlossomHill Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension |
| Janus Henderson Group | Series B Extension |
| H&D Asset Management | Series B |
| OrbiMed | Series B, Series B Extension, Series A |
| Brahma Capital | Series B Extension |
| Plaisance Capital Management | Series B |
| Hercules Bioventure Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Presented at the Mini Symposium at AACR 2026.
- Apr 21, 2026
Presented first preclinical data from new pan-kras inhibitor program at AACR 2026.
BlossomHill Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BlossomHill Therapeutics's valuation, stock price, and market status.
